Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Dec 30, 2019
|
staff reporter

NEW YORK – Eli Lilly said on Monday that its Phase III, LIBRETTO-531 clinical trial is

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Drug Discovery & Development

  1. BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

  2. Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

  3. OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

  4. Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

    Premium

  5. Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.